How to take Qlaira contraceptives (Bayer) and do they help with endometriosis?

Menopause is a concept familiar to every female representative, which means the onset of a period when reproductive function gradually begins to fade away. This phenomenon is due to major hormonal changes in the body: female hormones, in particular estrogens and progestins, are produced in ever smaller quantities, which significantly affects the functioning of all systems and mechanisms. Recently, more and more often, specialists prescribe hormonal contraceptives during menopause. Their action helps in the fight against the correction of the menstrual cycle up to its complete disappearance at the time of menopause, as well as with the manifestation of other uncomfortable sensations. One of these medications is Qlaira. The main features of Clair and its use during menopause are presented in this article.

Pharmacological properties of the drug Qlaira

Pharmacodynamics . Qlaira is a combined oral contraceptive used to prevent pregnancy. Each colored active tablet contains a small amount of female sex hormones (estradiol valerate in combination with dienogest). 2 white tablets do not contain active ingredients and are called inactive tablets (placebo). Contraceptives containing 2 hormones are called combined oral contraceptives (COCs). In addition to the contraceptive effect, PDAs have a number of other positive effects. When using COCs, the intensity and duration of menstrual bleeding decreases. As a result, the risk of anemia is reduced. Menstruation may become less painful or painless. It has been found that when using high-dose COCs (50 mcg ethinyl estradiol), the risk of developing serious diseases is reduced. These include benign diseases of the mammary glands, ovarian cysts, infectious and inflammatory diseases of the pelvic organs, ectopic pregnancy, endometrial and ovarian cancer. It is possible that a decrease in the level of these diseases is also observed with the use of low-dose oral contraceptives, but this fact has been confirmed only for endometrial and ovarian cancer.

Release form

Tablets with a thin film coating, round, biconvex. A total of five types of tablets are produced:

• Marked "DD". There are 2 tablets in the package. The shell is yellow, the core is white.
• Marked "DJ". There are 5 tablets in a package. The shell is pink, the core is white.
• Marked "DH". There are 17 tablets in a package. The shell is pale yellow, the core is white.
• Marked "DN". There are 2 tablets in the package. The shell is red, the core is white.
• Marked “DT”. There are 2 tablets in the package. The shell is white, the core is white.

Each package of Qlaira contains four types of active tablets, each type containing several different doses of hormones. Two dark yellow tablets contain 3 mg estradiol , five medium red tablets contain 2 mg estradiol and 2 mg dienogest , 17 light yellow tablets contain 2 mg estradiol and 3 mg dienogest , and two dark red tablets contain 1 mg estradiol . The package also contains two inactive white tablets.

Use of the drug Qlaira

Each package contains 26 colored active tablets and 2 white inactive tablets. Take 1 tablet 1 time per day at approximately the same time, with a small amount of water, regardless of meals. When combined oral contraceptives are used correctly, the incidence of unwanted pregnancy is approximately 1% per year. The incidence of unwanted pregnancy may increase if a dose is missed or due to improper use. Preparing packaging. To make it easier to control your pill intake, the package comes with 7 sticker strips with the names of the days of the week. Select a strip that begins on the day corresponding to the start of taking the drug (for example, for the medium, use a strip starting with “Wed”). Stick a strip on top of the Qlaira package in the place where it says “Stick the strip here”, so that the 1st day of taking the drug is above the tablet numbered “1”. If there is a specified day above each tablet, you can control the intake of tablets. You must take the tablets one at a time, following the direction of the arrows, until you finish taking all 28 tablets. Usually, menstrual-like bleeding begins when you take the second dark red tablet or white tablet and may not stop until you start taking a new tablet from the package. Some women continue bleeding even after taking the first pills from a new package. There is no break before starting to take tablets from a new package; the use of tablets from the next package begins the next day after the end of taking tablets from the current package, even if menstrual-like bleeding continues. Thus, the start of taking a new package will be on a certain day of the week, and each month the start of menstruation will be approximately the same day of the week. When taking the drug in the manner described above, the contraceptive effect is also maintained when taking inactive tablets for 2 days. How to start taking Qlaira. No hormonal contraceptives were used in the previous month. Taking the pills should start on the 1st day of the menstrual cycle (1st day of menstrual bleeding). Switching from another PDA, contraceptive vaginal ring or transdermal patch. The use of Qlaira should be started the day after taking the last active tablet of the previous COC. Do not take inactive tablets from the package of the previous PDA (if any), but start taking Qlaira tablets without interruption. When using a combined contraceptive vaginal ring or transdermal patch, it is advisable that a woman begin using Claira on the day of removal of the product or as recommended by a doctor. Switching from a progestogen-based method (mini-pills, injections, implants) or a progestogen-containing intrauterine system. You can start taking Qlaira any day after you stop taking the mini-pill (in the case of an implant or intrauterine system - on the day of their removal, in the case of an injection - instead of the next injection). However, in all cases it is recommended to additionally use a barrier method of contraception during the first 9 days of taking the pills. After a miscarriage. On doctor's recommendation. After childbirth. Taking Qlaira begins after the end of the first physiological menstrual cycle. In some cases, this is possible earlier (on the recommendation of a doctor). However, if sexual intercourse has already taken place, then before starting to use the PDA it is necessary to exclude the possibility of pregnancy or wait until menstruation. When using the drug during breastfeeding, as well as in the absence of certainty about the timing of starting use of the drug, prior consultation with a doctor is necessary. What to do if you miss a pill Inactive pills . If you miss taking a white tablet (2 tablets at the end of the package), there is no need to take it later, since it does not contain active ingredients, and the contraceptive effect of the drug is not reduced. It is important to take your next tablet at the usual time and remove any forgotten inactive white tablets from the package. The contraceptive effectiveness of the drug may decrease if the period during which active tablets are not used is accidentally increased. If you miss the last white tablet in a pack, take the first tablet in the next pack at the usual time. Active tablets (1–26 tablets per pack). Depending on the day of the menstrual cycle on which the active pill was missed, additional contraception may be necessary (use of a barrier method of contraception - a condom). Tablets must be taken according to the recommendations given (see also Guidelines for use in case of a missed tablet ). If the delay in taking the active pill does not exceed 12 hours, the contraceptive effect of Qlaira is not reduced. The missed pill should be taken as soon as possible. The following tablets in this pack should be taken at the usual time. If the delay in taking the active pill exceeds 12 hours, the contraceptive effect may be reduced. Depending on the day of the menstrual cycle on which the active pill was missed, additional contraception (using a barrier method of contraception - a condom) may be necessary (see also Principles of use in case of a missed pill ). Principles of use in case of a missed pill . If you miss more than 1 active tablet, consult a doctor. If you miss taking the 1st active tablet (delay in taking more than 12 hours) and if taken during the 1st week before missing sexual intercourse, you must adhere to the following recommendations:

• Days 1–9 of the menstrual cycle - additional consultation with a doctor;
• On the 10th–17th day of the menstrual cycle, take the forgotten pill, all subsequent pills at the usual time, even if you need to take 2 pills on 1 day, use additional methods of contraception for the next 9 days (condom);
• On the 18th–24th day of the menstrual cycle, do not take the forgotten pill, but start with the 1st tablet of the new package, use additional methods of contraception in the next 9 days;
• On the 25th–26th day of the menstrual cycle, take the forgotten pill, all subsequent pills at the usual time, even if you need to take 2 pills on 1 day, there is no need for additional methods of contraception;
• On the 27th–28th day of the menstrual cycle, do not take the missed pill and continue taking the pills at the usual time; there is no need for additional methods of contraception.

If you miss taking another tablet, do not take more than 2 active tablets per day . If the start of taking tablets from the next package is missed or ≥1 tablet is missed during the 3rd–9th day of the current package, there is a risk of pregnancy (if there was sexual intercourse within 7 days before the missed tablet). In this case, you need to consult a doctor. Depending on the number of pills missed (especially on days 3–24) and the closer they are to the inactive pill phase, the risk of decreased contraceptive effectiveness increases. If a woman misses a dose of active tablets and does not have her expected menstrual period while taking the last tablets in the pack, the possibility of pregnancy must be ruled out. Before starting to take tablets from a new package, you should consult a doctor. If vomiting or severe diarrhea occurs while taking any of the 26 active tablets of Qlaira, the absorption of the active substances may be reduced. If vomiting develops within 3-4 hours after taking the tablets, this is similar to skipping a dose of the drug; you must follow the instructions for missed tablets. If diarrhea is severe, you should consult a doctor. The presence of vomiting or diarrhea when taking the last 2 inactive white tablets does not affect the contraceptive effectiveness of the drug. Stop taking the drug . You can stop taking Qlaira at any time. If you stop using the drug to become pregnant, you must wait until the next menstrual bleeding begins before conceiving. This will help in determining the due date.

Storage conditions

It is necessary to store Qlaira tablets in an airtight container until it is time to open it. If you have already started taking the tablets, they should not be stored longer than the scheduled dosage plan.

Store the drug in a cool, dry place where the temperature does not exceed 30° C.

It is not recommended to store pills or other medications in the bathroom or near the sink. Do not leave it on a windowsill or in a car. Heat and dampness destroy some components of the drug.

The drug should be kept in a place inaccessible to children.

Contraindications to the use of the drug Qlaira

Combined oral contraceptives should not be used if you have one of the following conditions or diseases:

• deep vein thrombosis of the lower extremities, pulmonary embolism or thrombosis of another location, currently or in the past;
• acute coronary syndrome (ACS) and acute cerebrovascular accident (ACVA) - ischemic or hemorrhagic in nature - currently or in the past;
• prodromal manifestations of ACS (angina) or stroke (transient ischemic attack - TIA) currently or in the past;
• migraine accompanied by focal neurological symptoms (impaired vision, speech, paresthesia or paresis of various localizations);
• diabetes mellitus with vascular complications;
• pancreatitis associated with hyperlipidemia, currently or in history;
• liver disease currently or in history until liver function tests return to normal;
• hormone-dependent malignant tumors of the genital organs or breast, currently or in history;
• benign or malignant liver tumor currently or in history;
• vaginal bleeding of unknown origin;
• established or probable pregnancy;
• hypersensitivity to estradiol valerate or dienogest, or other components of the drug.

You should immediately stop using the drug if one of the above conditions occurs and switch to taking non-hormonal contraceptives (see also section Special instructions ).

The effect of pills on weight loss

The most reliable means are monophasic tablets.
They include 2 components - estrogen and progesterone. These substances are contained in each tablet in the same amount. Biphasic products contain 2 versions of estrogen and progestin - they differ in dosage. In addition, there are three-phase drugs that include 3 combinations of hormonal components used during one cycle.

Regardless of the type of birth control pill, they have a similar principle of action. Progesterone blocks ovulation, and estrogens control the menstrual cycle.

All oral contraceptives differ in the quantity, structure and proportions of hormones that are included in one tablet.

Desogestrel, gestodene, and cyproterone are used as gestagenic elements. These substances are characterized by varying degrees of activity.

Based on the dosage of estrogen, birth control pills can be divided into the following categories:

1. Microdosed preparations - include 20 mcg estradiol,
2. Low-dose products - contain 30 mcg estradiol,
3. High-dose medications - they contain 40 mcg of the substance, they are used to treat hormonal pathologies and prevent unwanted pregnancy during hormonal imbalance,
4. Mini-pills, also called progestin pills, do not contain estrogen.

A lot of research has been done on the effects of estrogen on the female body. They made it possible to analyze the metabolic capabilities of these elements.

With a decrease in the content of estradiol in the female body, a decrease in the volume of potassium is observed. There is a risk of muscle loss and sleep disturbances. Serious consequences of decreased hormone levels include loss of weight control.

Be sure to read: Pros and cons of losing weight quickly with the ECA fat burner

Contraceptives for weight loss are used taking into account certain features:

• Products that contain less than 20 mcg of a hormonal component can stimulate weight loss in a certain state of the female body,
• Pills that include 30 mcg of estrogen have no effect on weight,
• Drugs that contain more than 50 mcg of a hormonal substance provoke the development of obesity.

Preparations based on artificial analogues of progesterone and estradiol include 30 mg of estrogens and are an excellent means of preventing unwanted pregnancy. They can be used by young women who have not yet given birth, and patients of late reproductive age.

In addition to the contraceptive effect, these medications have a therapeutic effect and prevent the occurrence of various gynecological pathologies. With their help, it is possible to maintain normal estrogen levels.

The instructions for using low-dose products indicate that the estrogen component of such tablets can cause weight gain. This is due to the ability to retain fluid in the body.

Low-dose estrogen contraceptives include the following:

1. Lindinet 20 - are monophasic tablets that have a yellow shell. The composition contains ethinyl estradiol and gestodene, which is more active than progesterone.
2. Triziston is a three-phase drug that comes in the form of white tablets. The medicine contains ethinyl estradiol and levonorgestrel. They are used for contraception to combat hormone-dependent cycle disorders.
3. Yarina is a monophasic drug that is produced in tablet form. The tablets are yellow in color and film-coated. Contains ethinyl estradiol and drospirenone. The gestagenic component of the drug can prevent weight gain, which is caused by estrogen-dependent fluid retention.
4. Janine - the medicine is produced in the form of white tablets, which have a monophasic effect. They are produced on the basis of ethinyl estradiol and dienogest. The medicine has a monophasic effect. If used correctly for 1 year, the probability of pregnancy does not exceed 1%. The dragee should be drunk in accordance with the schedule indicated on the package, taking weekly breaks.
5. Tri-mercy is a three-phase drug that contains ethinyl estradiol and desogestrel in different dosages.

Side effects of the drug Qlaira

When taking Qlaira, the following side effects may develop:

Including: 1 - headache caused by changes in blood pressure; 2 - migraine with or without aura; 3 - increased intra-abdominal pressure; 4 - generalized itching and itching with rash; 5 - macular rash; 6 - allergic dermatitis and urticaria; 7 - feeling of skin tightness; 8 - pain in the mammary glands and nipples, nipple disorders; 9 - irregular menstruation.

In addition to these side effects, cases of skin diseases such as erythema nodosum and erythema multiforme, as well as increased sensitivity and discharge from the mammary glands have been observed in women taking COCs with ethinyl estradiol. Although these symptoms were not observed during clinical studies of the drug, the possibility of their occurrence during use of the drug cannot be ruled out. In women with hereditary angioedema, administration of exogenous estrogens may induce or worsen symptoms of angioedema. Thrombosis . There is no data on the risk of thrombotic complications while taking Qlaira. The following warnings are based on data from studies of other COCs containing ethinyl estradiol. However, it is unknown whether they apply to the use of Clair. Deep vein thrombosis develops quite rarely. The risk of developing venous thromboembolism is highest during the 1st year of taking COCs (compared to subsequent years of their use). The risk of thrombosis in women taking COCs is slightly higher than in those who do not use them. When using COCs, you should stop smoking, especially if the woman is over 35 years old. Although slight increases in blood pressure have been reported in many women taking COCs, clinically significant increases in blood pressure occur very rarely. If blood pressure increases when using COCs, it is possible to stop taking them. In women taking COCs during prolonged immobilization or during surgical interventions, the risk of developing thrombosis increases. Taking COCs should be stopped several weeks before surgery or during forced immobility; it can be resumed during the period of convalescence after consulting a doctor. The risk of developing thrombosis in women during the postpartum period is increased, so you can start using Qlaira only as prescribed by a doctor. If symptoms of possible thrombosis develop, it is necessary to stop using the drug. Tumors. Breast cancer was slightly more likely to be diagnosed in women taking COCs compared to women of the same age who did not use them. There is no data on the causal relationship of the tumor with taking COCs. This may be due to more frequent medical examination of women taking COCs. This risk gradually decreases after you stop taking COCs. It is necessary to regularly examine the mammary glands to identify any lumps. In isolated cases, benign and, less frequently, malignant liver tumors were noted in patients taking COCs, which in some cases led to intra-abdominal bleeding. It is necessary to consider the possibility of this complication when intense abdominal pain occurs. An important risk factor for the development of cervical cancer is the persistence of papillomavirus. Some epidemiological studies suggest an additional increase in this risk with long-term use of COCs, but this remains controversial because the extent to which the studies account for associated risk factors such as cervical screening and sexual behavior, including the use of barrier methods of contraception, remains unclear. .

Special instructions for the use of the drug Qlaira: General instructions . When using the drug Qlaira, calendar and temperature methods are not used; they may be unreliable, since the combined oral contraceptive changes the normal fluctuations in body temperature and the properties of cervical mucus characteristic of the menstrual cycle. Qlaira, like other CCPs, does not protect against HIV infection (AIDS) and other sexually transmitted diseases. If you have one of the following conditions or diseases when using the drug Qlaira, constant monitoring is necessary: ​​smoking, diabetes mellitus, excess body weight, hypertension (arterial hypertension), damage to the heart valves or cardiac arrhythmias, superficial phlebitis, varicose veins, thrombosis of various locations, ACS or stroke in close relatives, migraine, epilepsy, hypercholesterolemia or hypertriglyceridemia in close relatives currently or in history, breast cancer in close relatives currently or in history, liver or gallbladder disease, Crohn's disease or ulcerative colitis, systemic lupus erythematosus, hemolytic uremic syndrome, sickle cell anemia, alopecia, porphyria, herpetic infection, Sydenham's chorea, current or past chloasma (avoid prolonged exposure to the sun or ultraviolet radiation), hereditary angioedema (drugs containing estrogens may induce or increase its symptoms). If possible signs of thrombosis or stroke occur, the use of the drug should be stopped immediately. When using oral contraceptives during the first few months, irregular vaginal bleeding is possible during the intermenstrual period, but the regimen of use of the drug is not changed; these conditions are relieved as they adapt to the drug (usually after 3 cycles of taking tablets). If the drug Qlaira is taken incorrectly or irregularly, or if there is severe vomiting or diarrhea, or if there is no expected bleeding after the 26th day of the menstrual cycle 2 times in a row, it is necessary to consider the possibility of pregnancy; the drug should not be resumed until pregnancy has been ruled out. During pregnancy and breastfeeding . The drug is not used during pregnancy or if pregnancy is suspected. If you are planning a pregnancy, you can stop using the drug at any time. The drug Qlaira is not recommended for use during breastfeeding. Children . There are no data regarding the use of the drug in children and adolescents under 18 years of age. There is no data on the effect on reaction speed when driving vehicles or working with machinery.

Pharmacodynamics and Pharmacokinetics

The estrogen in Qlaira is estradiol valerate , an ester of human 17β-estradiol (1 mg estradiol valerate corresponds to 0.76 mg 17β-estradiol ). This estrogen is different from ethinyl estradiol or its precursor mestranol , used in other COCs and containing an ethyl group 17a, which causes more stable metabolic activity , but at the same time has effects on the liver.

Dienogest (DNG) is a progestogen with previous clinical trials. It has a pronounced effect on the endometrium. Structurally derived from nortestosterone, it has the characteristics of nortestosterone and progestogen derivatives. DNG does not have androgenic activity , but does have antiandrogenic activity.

Pharmacokinetics

Estradiol valerate

Absorption: Following oral administration of estradiol valerate, it is completely absorbed by the intestinal mucosa. After initial absorption, E2V is hydrolyzed to produce E2 and valeric acid through a metabolic process in the gastrointestinal mucosa and liver.

Metabolism: metabolism occurs in the gastrointestinal mucosa and liver. Estradiol valerate undergoes extensive changes in first-pass metabolism, resulting in increased serum . Approximately 95% of an oral dose of estradiol valerate is metabolized before it enters the systemic circulation , so the bioavailability of E2V is approximately 3-5%. Metabolism of E2 in the intestinal mucosa and liver leads to the conversion to estrone (E1) and estriol (E3). Both E1 and E3 are metabolized into sulfate and glucuronide forms . These forms of limited cell penetration partly explain their low effectiveness. Estrone (E1) is converted to estrone sulfate (E1-S) by estrogen sulfotransefare and both can be converted back to E2. Since most of the orally absorbed E2 is converted to E1 and E1-S, E2 levels stabilize. Estrogens are further oxidized by liver cytochrome P450 , affecting the CYP3A4 and 1A2 pathways until completely eliminated.

Distribution: 5% of an oral dose of E2V reaches systemic circulation. E2 is bound to 38% of obligatory sex hormone globulin (SHBG), 60% to albumin , and 3% circulates in free form. The approximate volume of distribution is ~1.2 L/kg. Serum concentrations of E2 remain stable over the 28-day treatment period in the range of 0.0336-0.0647 ng/mL due to the steady state between E2-E1-E1-S. Recycling includes E1-S and estrone glucuronide . The half-life of estradiol is 1.5 hours, the terminal half-life of estradiol after oral administration is 13-20 hours and is dependent on the recirculation of estrogen sulfate .

Excretion: Estradiol and its metabolites are primarily excreted in the urine. 10% is excreted in feces.

Dienogest

Absorption: DNG is almost completely absorbed after oral administration and has high bioavailability (91%). There is no clinically established effect on the rate or extent of absorption of DNG by concomitant meals.

Distribution: DNG has a distribution volume of 46L. It circulates in serum with serum albumin (90%) and 9% in the form of free and bioavailable elements. Serum concentrations of DNG at steady state are: min 11.8ng/ml; max 82.9ng/ml.

Metabolism: The half-life from blood plasma is 12 hours. The substance is almost completely metabolized by cytochrome P450, the CYP3A4 isoform into pharmacologically inactive metabolites.

Excretion: DNG and its metabolites are excreted primarily by the kidneys. 86% of the hormone and its metabolites are eliminated after 6 days.

Interactions of the drug Qlaira

reduce the effectiveness of Qlaira or may cause bleeding: primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, ritonavir, nevirapine, penicillin, tetracycline, griseofulvin, drugs based on St. John's wort. Increase the concentration of the active substances of Qlaira in the blood plasma : antifungal drugs containing ketoconazole, erythromycin antibiotics. Qlaira may affect the effectiveness of lamotrigine. Laboratory research . Oral contraceptives may interfere with the results of some laboratory tests.

Reviews

Among gynecologists, the estrogen-gestagen contraceptive Qlaira has a positive reputation due to the fact that, compared to other oral contraceptives, this drug has a less intense effect on the functional state of the liver. In addition, the drug is easy to use and can be prescribed to women of all ages.

Reviews from women who are taking or have taken this drug note its pronounced contraceptive effect. In 80% of cases, women did not experience any adverse reactions to the medication.

There is a small percentage of women for whom this remedy is not suitable.

DIY gazebo photos and videos how to make and

Pharmaceutical interactions Pharmaceutically incompatible with ampicillin, barbiturates, theophylline, calcium gluconate, heparin and magnesium sulfate. Lincomycin is not compatible in one syringe or curtain

drip with kanamycin or novobiocin. Analogues of the drug Lincomycin Structural analogues of the active substance: Lincomycin-AKOS; Lincomycin hydrochloride; Lincomycin hydrochloride capsules 0.25 g; Lincomycin hydrochloride solution for injection 30; Neloren; Films with lincomycin. If there are no analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and look at the available analogues for the therapeutic effect.11. Volumetric valentines are a full-size gift. To make such a three-dimensional valentine you will need cardboard, you can take foil for the heart itself, scissors, thread or fishing line. Cut out blanks from cardboard, as shown in the figure, make cuts, and fasten them together. Hang a heart made of foil or cardboard on a thread or fishing line. That's all! The Valentine card can be folded, it will be flat, you can unfold it and place it on the table. Such a gift can be made together with the child for grandparents. 12. Valentine cards with buttons look very creative. These bright cards are so easy to make. Surely, many people have stocks of torn buttons. Now they can be applied.

OC withdrawal syndrome: adverse effects

In the case when a woman was prescribed oral contraceptives for the treatment of diseases of the reproductive organs and the establishment of the menstrual cycle (fibroids, endometriosis, algodysmenorrhea, uterine bleeding, etc.), the so-called withdrawal syndrome occurs when the drug is discontinued. In this case, signs of the disease may return and intensify.

During abrupt withdrawal of the drug, a woman may experience the following adverse reactions:

• Development of persistent depression;
• Skin rashes, acne;
• Excessive hair growth;
• Weakness and irritability;
• Changes in sexual desire;
• Development of breakthrough uterine bleeding;
• Strengthening the work of the sebaceous and sweat glands, as a result of which the patient’s hair becomes oily, acne and comedones appear on the skin;
• Headache;
• Nausea, vomiting.

If more than six months have passed since discontinuation of the OC, and withdrawal symptoms persist, you should consult a gynecologist.

How long does it take for the body to recover after stopping contraceptives?

Gynecologists say that if a woman felt well before starting to use the pills and during their use and took the drug solely to protect against pregnancy, then 2-3 months after stopping the use the body will function as before, that is, a complete recovery will occur.

What to do if you don't have your period?

The high proximity of Qlaira's composition to hormones that are naturally produced in the body reduces the risk of side effects. If after discontinuation of the drug there is a delay in menstruation, you should wait a little. As a rule, by the next cycle the situation has stabilized and menstruation begins to occur on time. At first, they may be more abundant and begin earlier, but after 2-3 months they return to the woman’s usual norm.

Source: www.OldLekar.ru

Cancellation of contraceptives before pregnancy

Many women are concerned about the question of whether it is possible to get pregnant after stopping the OC and how long after they should plan to conceive. If a woman decides to plan a pregnancy and stops taking birth control pills, then the body needs time for the menstrual cycle to fully recover; for this you should wait 2-3 months. During the use of OCs, the ovaries were in a state of “sleep” for a long time, therefore it is recommended to wait a certain period for their physiological function to resume. Of course, conception can occur immediately after stopping the pills, but such a pregnancy will be at risk, since there is a high chance of spontaneous miscarriage due to progesterone deficiency in the expectant mother’s body.

When is conception possible after stopping OK?

Many women worry that after prolonged use of oral contraception, pregnancy becomes more difficult, but medical practice refutes this fact. On the contrary, for women with ovarian hypofunction, gynecologists prescribe the use of OCs for 2-3 months, after which they recommend planning a pregnancy, since the chances of successful conception increase significantly, in addition, the chances of conceiving twins increase. After stopping the pills and actively planning pregnancy, conception occurs safely within 3-4 months.

Irina Levchenko, obstetrician-gynecologist, especially for the website Mirmam.pro

Source: mirmam.pro